Coverage of over-the-counter contraceptive drugs, devices, and products by insurers and medical assistance required; and reports required.
HF1485 requires Minnesota health plans to cover over-the-counter contraceptive drugs, devices, and products, and it bars insurers from imposing cost-sharing, referral requirements, or delays for contraceptive methods and services. The bill expands the definition of contraceptive method to include both prescription and over-the-counter products approved by the FDA to prevent unintended pregnancy, and it requires health plans to cover at least one FDA-approved contraceptive method in each category, with special rules ensuring coverage of all OTC contraceptives purchased at a pharmacy without a prescription. It also requires coverage when a provider determines a particular contraceptive is medically necessary for an enrollee.
The bill also amends Minnesota Medical Assistance law to cover all OTC contraceptives even when they are not prescribed, and it preserves existing Medicaid coverage for other OTC drugs while adding this new contraceptive category. In addition, it requires Medical Assistance to cover a 12-month supply of prescription contraceptives when prescribed, and it directs the Department of Commerce, working with Health and Human Services, to provide public outreach and annual reports on OTC contraceptive coverage and costs. Most provisions take effect January 1, 2026, with reporting beginning in 2027.
The bill’s impact on state law is to broaden mandated contraceptive coverage in both the private insurance market and Medicaid, while limiting insurers’ ability to use utilization controls, cost-sharing, or prescription-status restrictions for OTC contraceptives. It would amend Minnesota Statutes sections 62Q.522 and 256B.0625 to create a clearer statutory entitlement to OTC contraceptive coverage and to require administrative reporting on utilization and fiscal effects.
The general sentiment reflected by the bill text is strongly supportive of contraceptive access and affordability, with the structure of the bill emphasizing removal of barriers to obtaining birth control. Because no committee transcripts or votes were provided, there is no recorded legislative debate or vote history to indicate broader support or opposition beyond the bill’s policy design.
Notable points of contention likely center on cost to health plans and the state, the requirement that insurers cover all OTC contraceptives at point of sale without a prescription, and the mandate that plans defer to a provider’s medical-necessity determination. Another possible issue is the interaction with high-deductible and health savings account rules, since the bill preserves an exception if pre-deductible coverage would affect HSA eligibility or catastrophic plan status.
HF1485 would amend Minnesota’s insurance and Medicaid statutes to require coverage of over-the-counter contraceptives, prohibit cost-sharing for contraceptive methods and services, and require Medicaid to cover OTC contraceptives regardless of whether they are prescribed. It also requires a 12-month supply of prescription contraceptives in Medical Assistance when prescribed, and it directs state agencies to conduct outreach and report on utilization and costs.
The bill appears to have a pro-access, pro-coverage policy orientation, aiming to reduce financial and administrative barriers to contraception. No committee transcripts or votes were provided, so there is no documented public debate in the supplied materials to show opposition or support beyond the bill’s text.
Likely areas of contention include the fiscal impact on insurers and the state, the mandate to cover all OTC contraceptives at pharmacy point-of-sale without a prescription, and the requirement to defer to a provider’s medical-necessity determination. Stakeholders concerned about premium increases, Medicaid spending, or plan design flexibility would be the most likely sources of opposition, while reproductive health advocates would likely support the bill.